

REQUIRED: Demographics &amp; Most recent H&amp;P, Clinical Notes, and Medication List

**PATIENT INFORMATION**

Patient Name	Date of Birth		Gender	<input type="checkbox"/> Male	<input type="checkbox"/> Female
Address					
Home Phone	Work Phone	Cell Phone			

**INSURANCE INFORMATION: Please fax a copy of the insurance card(s) with this form (front and back)**
**MEDICAL INFORMATION**

Weight (kg)	Height	Allergies			
Diagnosis	ICD-10				
Patient Status	<input type="checkbox"/> New to Therapy	<input type="checkbox"/> Continuing Therapy	Next Treatment Date		
Line Access	<input type="checkbox"/> Port	<input type="checkbox"/> PICC	Other: _____	Lumens	<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 3

**THERAPY ORDER**
**Dosing for Initial Phase and Maintenance** (10mg/kg until week 12, then 5mg/kg starting at week 16)

 **Initial Phase:**

- Nulojix \_\_\_\_\_ mg IV on Day 1 (day of transplant) and Day 5, at the end of week 2, week 4, week 8, and week 12 after transplant.
- Then \_\_\_\_\_ mg IV at the end of week 16 after transplant and every 4 weeks (plus or minus 3 days) thereafter x 1 year

 **Maintenance Phase:**

- Nulojix \_\_\_\_\_ mg IV every 4 weeks x 1 year
- Transplant Date \_\_\_\_\_
- Patient Weight at time of transplant \_\_\_\_\_ (kg)
- Prescribed doses will be rounded to be evenly divisible by 12.5mg.
- The total infusion dose of Nulojix should be based on the actual body weight of the patient at the time of transplant, and should not be modified during the course of the therapy, unless there is a change in the body weight of greater than 10%.
- If the patient has had a >10% weight change, the physician will be notified for dose change recommendations.

**Flush orders:** Sodium Chloride 0.9% flush 5-10ml per protocol pre/post infusion

**Lab Orders:**  Required Annual TB testing  Other: \_\_\_\_\_

 Labs to be drawn by:  Home Health Nurse  Referring Provider

**PROVIDER INFORMATION**

 By signing this form and utilizing our services, the prescriber is authorizing *Pharmacy Specialists* and its employees to serve as their prior authorization and designated agent in dealing with medical and prescription insurance companies. The prescriber certifies that the use of the indicated treatment is medically necessary, and the prescriber will supervise the patient's treatment.

Prescriber Name	Signature		Date	
Prescriber NPI	Phone	Fax	Contact Person	

REQUIRED: Demographics & Most recent H&P, Clinical Notes, and Medication List

**PATIENT INFORMATION**

Patient Name

**REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING AND INSURANCE APPROVAL**

- Include signed and completed order
- Include patient demographic information and insurance information
- Include patient's medication list
- Supporting clinical notes (H&P) to support primary diagnosis
- PICC/Central line placement confirmation (if applicable)
- Other medical necessity: \_\_\_\_\_

**REQUIRED INFORMATION**

- TB screening test completed within 12 months - attach results       Positive    Negative
- EBV serostatus - attach result
- Nulojix Distribution Program
  - Patient **MUST** be enrolled in the Nulojix Distribution Program (NDP) and have a patient ID number from NDP.
  - Call 855-511-6180 to enroll patient.
  - Nulojix Distribution Program Patient ID#: \_\_\_\_\_ (REQUIRED FOR MEDICATION TO BE ORDERED)

**REFERRAL AND INSURANCE APPROVAL PROCESS:** Please submit a completed order form and all required documentation. *Pharmacy Specialists* will complete insurance verification and submit all required documentation to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. Financial responsibility will be reviewed with the patient. Any available co-pay assistance programs will be discussed with the patient as needed. Thank you for the referral.

**IMPORTANT WARNING:** The information contained in this document is legally privileged and confidential information intended only for the use of the individual or entity to which it is addressed. If the reader of this document is not the intended recipient, you are hereby notified that any viewing, dissemination, distribution, or copy of this document is STRICTLY PROHIBITED. If you have received and/or are viewing this document in error, please immediately notify the sender and destroy all copies if you have received this document in error.